The economic and clinical burden of early versus late initiation of celecoxib among patients with osteoarthritis
Ahmed Shelbaya,1,2 Caitlyn T Solem,3 Chris Walker,4 Yin Wan,3 Courtney Johnson,3 Joseph C Cappelleri1 1Pfizer Inc., New York, NY, 2Columbia School of Public Health, New York, NY, 3Pharmerit International, Bethesda, MD, USA; 4Pfizer Ltd., Tadworth, Surrey, UK Objective: This study aimed to evaluate t...
Saved in:
Main Authors: | Shelbaya A (Author), Solem CT (Author), Walker C (Author), Wan Y (Author), Johnson C (Author), Cappelleri JC (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2018-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Economic Outcomes Related to Persistence and Dosing of Celecoxib in Patients with Osteoarthritis (OA) Using a Retrospective Claims Database Analysis
by: Johnson C, et al.
Published: (2020) -
Evaluating the Cost-Effectiveness of Celecoxib versus Ibuprofen and Naproxen in Patients with Osteoarthritis in United Arab Emirates Based on the PRECISION Trial
by: Chirikov VV, et al.
Published: (2021) -
Controlled release of celecoxib inhibits inflammation, bone cysts and osteophyte formation in a preclinical model of osteoarthritis
by: A. R. Tellegen, et al.
Published: (2018) -
Análisis coste-efectividad del empleo de celecoxib en el tratamiento de la artrosis Cost-effectiveness analysis of the use of celecoxib for the treatment of osteoarthritis
by: A. Moreno, et al.
Published: (2003) -
Patient and economic burdens of postherpetic neuralgia in China
by: Yu SY, et al.
Published: (2019)